- The Wall Street Journal•52 minutes ago
Sanofi and Novo Nordisk, two of Europe’s health-care companies most exposed to the falling prices for insulin products in the all-important U.S. market, gave dramatically diverging outlooks in the third ...
- Reuters•2 hours ago
Novo Nordisk remains committed come what may to the U.S. insulin market, where price pressure are likely to continue into 2019, Chief Executive Lars Rebien Sorensen said on Friday. "We have no intentions ...
- Financial Times•2 hours ago
Shares in Denmark's Novo Nordisk, the world's largest insulin producer, plunged on Friday after it slashed its long term profit target, souring the end of chief executive Lars Rebien Sorensen's 16 years ...
Novo Nordisk A/S (NVO)
NYSE - NYSE Real Time Price. Currency in USD
|Bid||34.97 x 4400|
|Ask||35.06 x 4400|
|Day's Range||40.85 - 41.35|
|52wk Range||39.03 - 59.00|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||19.82|
|Avg Vol (3m)||3,410,412|
|Dividend & Yield||1.41 (3.51%)|